Wijnen PAHM, Bekers O, Drent M.
Development of cocaine-induced interstitial lung damage in two CYP2C and VKORC1 variant allele carriers. 
Mol Diagn Ther 2011; 15: 177-180.

Wijnen PAHM, Linssen CFM, Haenen GR, Bekers O, Drent M.
Variant VKORC1 and CYP2C9 alleles in patients using coumarin based anticoagulants associated with risk of diffuse alveolar haemorrhage.
Mol Diagn Ther 2010; 14: 23-30.

Wijnen PAHM, Bekers O, Drent M.
Relationship between drug-induced interstitial lung diseases and CYP polymorphisms.
Curr Opinion Pul Med 2010; 496-502.

Wijnen PAHM, Limantoro I, Drent M, Bekers O, Kuijpers PMJC, Koek GH.
Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity.
Ann Clin Biochem 2009; 46: 527-30.

Wijnen PAHM, Drent M, Nelemans P, et al.
Role of cytochrome P450 polymorphisms in pulmonary drug toxicity.
Drug Saf; 2008: 31: 1125-34.

Ansell J, Hirsh J, Hylek E, et al.
Pharmacology and management of the vitamin K antagonists: chest physicians evidence-based clinical practice guidelines (8th edition).
Chest 2008;133: 160-198.

Sconce E, et al.
Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin.
Blood 2007;109: 2419-23.

Bakker JA, Drent M, Bierau J.
Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of ILD.
Curr Opion Pulm Med 2007; 13: 458-63.

Genelex Corporation
Physician Guidelines: Drugs Metabolized by Cytochrome P450’s
2005

Levien T, Baker D.
Cytochrome P450 Drug Interactions 
Therapeutic Research Center Pharmacist’s Letter / Prescriber’s Letter 2003